Edition:
United States

Biotechnology & Medical Research

Jounce Therapeutics Reports Q2 Loss Per Share Of $0.82

Aug 7 (Reuters) - Jounce Therapeutics Inc ::JOUNCE THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.82.Q2 EARNINGS PER SHARE ESTIMATE $-0.72 -- REFINITIV IBES DATA.JOUNCE THERAPEUTICS - EXPECTS EXISTING CASH, CASH EQUIVALENTS, INVESTMENTS TO BE ENOUGH FOR OPERATING...

Friday, 7 Aug 2020 06:30am EDT

Mersana Therapeutics Announces Q2 Loss Per Share $0.33

Aug 7 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.33.Q2 EARNINGS PER SHARE ESTIMATE $-0.30 -- REFINITIV IBES DATA.MERSANA THERAPEUTICS - CASH, EQUIVALENTS & MARKETABLE SECURITIES AS OF...

Friday, 7 Aug 2020 06:00am EDT

Geron Reports Q2 Loss Per Share Of $0.06

Aug 6 (Reuters) - Geron Corp ::ORATION REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND CURRENT EVENTS.Q2 LOSS PER SHARE $0.06.Q2 EARNINGS PER SHARE ESTIMATE $-0.06 -- REFINITIV IBES DATA.GERON - CONTINUES TO EXPECT PATIENT ENROLLMENT TO BE COMPLETED BY END OF Q1 OF 2021 ON IMERGE PHASE 3 CLINICAL...

Thursday, 6 Aug 2020 04:05pm EDT

Dynavax Announces Second Quarter 2020 Financial Results

Aug 6 (Reuters) - Dynavax Technologies Corp ::DYNAVAX ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.53.Q2 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $200.7 MILLION AT JUNE 30, 2020.QTRLY PRODUCT REVENUE,...

Thursday, 6 Aug 2020 04:02pm EDT

Expansion & New Markets

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.